1 / 21

Literature Review

Literature Review. Peter R. McNally, DO, FACP, FACG University Colorado Denver School of Medicine Center for Human Simulation Aurora, Colorado 80045. Gilard M 1 , Arnaud B 2 , Cornily JC 1 , Le Gal G 3 , Lacut K 3 , Le Calvez G 2 , Mansourati J 1 , Mottier D 2 , Abgrall JF 2 , Boschat J 1 .

biana
Download Presentation

Literature Review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Literature Review Peter R. McNally, DO, FACP, FACG University Colorado Denver School of Medicine Center for Human Simulation Aurora, Colorado 80045

  2. Gilard M1, Arnaud B2, Cornily JC1, Le Gal G3, Lacut K3, Le Calvez G2, Mansourati J1, Mottier D2, Abgrall JF2, Boschat J1. Influence of omeprazoleon the antiplatelet action of clopidogrel associated withaspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60. 1Dept Cardiology, 2Dept Hematology, INSERM 0502, 3Center for Clinical Investigation EA3878 and Dept Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France

  3. Introduction • Platelet activation & aggregation play an important role in the pathogenesis of arterial thrombosis and can lead to acute coronary syndrome (ACS) associated with percutaneous coronary intervention (PCI). • Clopidogrel (Plavix*) a thienopyridine, inhibits platelet activation induced by adenosine diphosphate (ADP). • Clopidogrel metabolites form an inactive disulfide bond with the platelet P2Y12 ADP receptor, inhibiting platelet reactivity. • Clopidogrel is a prodrug, needing hepatic metabolism to acquire platelet anti-aggregation properties. Small DS, et al. Effects of PPI Lansoprazole on pharmacodynamics of Prasugrel and Clopidogrel. J Clin Pharm. 2008;48:475-84.

  4. Introduction • Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) provides an functional index of platelet reactivity to clopidogrel. • The higher the platelet reactivity index (PRI) the more frequently thrombosis occurs with clopidogrel treatment. • The hepatic CYP450 isoenzyme CYP2C19 is the dominant enymatic pathway of prodrug (clopidogrel) activation. Gilard M, et al. J Thromb Hemost 2006;4:2508-9

  5. Introduction • Omeprazole (OMP) is a racemic compound commonly used to suppress gastric acid production in the treatment of peptic ulcer disease and Gastroesophageal Reflux Disease (GERD). • OMP is a prodrug, predominantly metabolized by hepatic CYP450 isoenzyme CYP2C19. • Competitive inhibition of the CYP2C19 metabolic pathway by OMP may decrease Clopidogrel activation thereby decreasing PRI values and increasing risk for ACS. Gilard M, et al. J Thromb Hemost 2006;4:2508-9

  6. Hepatic CYP450 Activation of Prodrugs: PPIs and Clopidogrel Active Metabolites Pro Drugs Benzimidazole PPI’s CYP-3A4 Sulfenamide CYP-2C19 Clopidogrel R-130964 Competitive Inhibition ↓ Active Metabolites Ishizaki T, et al. Aliment Pharmacol Ther. 1999;13:Suppl 3:27-36. Small DS, et al. J Clin Pharmacol. 2008;48:475-484.

  7. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Aim • The authors sought to test the hypothesis that OMP reduces the biological action of clopidogrel (platelet reactivity index or PRI) , probably due to competitive inhibition of the CYP2C19 pathway. • In a prospective, randomized double-blind study, Gilard, et al, evaluated the impact of OMP 20mg/day vs. placebo on clopidogrel effect by measuring platelet phosphorylation-VASP as expressed as PRI.

  8. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Design: Prospective, blinded, placebo controlled, randomized trial • Consecutive patients undergoing elective coronary stent implantation were considered for inclusion • All patients gave written informed consent • Controlled Treatment (all patients received) • Aspirin 75 mg/day • Clopidogrel 300 mg loading, followed by 75 mg/day • Randomization Treatment • Omperazole 20 mg or Placebo • Treatment daily for 7 days

  9. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Design Total Assessed for Eligibility, N=354

  10. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Design: Study Population • Exclusion Criteria • Previous treatment with Clopidogrel • Previous treatment with PPI • History of thrombocytopenia < 150K • Bleeding disorder • Liver disease • Peptic ulcer disease • Pregnancy

  11. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Design: Study Evaluations • Conducted on Day 1 (pre-Clopidogrel) and 7 days after (clopidogrel + OMP vs. placebo) • Platelet Reactivity Evaluation • Vasodilator-Stimulated Phosphoprotein (VASP) Biodis-Stago, Asnieres, France. • Platelet mean fluorescence intensity (MFI) • Platelet Reactivity Index (PRI)

  12. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Design: Study Evaluations Platelet Reactivity Index (PRI) calculation: % PRI = (MFI[PGE1] - MF1[PGE1+ADP] X 100 MFI (PGE1) Established Criteria for Clopidogrel response: Good % PRI < 50% Poor % PRI > 50% Barragan P et al. Catheter Cardiovasc Interv. 2003;107:32-7

  13. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Results: Demographics

  14. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Results: Demographics Table 1.

  15. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Results: Platelet Reactivity Index (PRI) Figure 1. P = NS P < 0.0001

  16. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Results: Variation of PRI Figure 2. P < 0.0001

  17. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Study Results: Summary • Baseline demographic characteristics between the Omp and placebo treated groups were statistically similar, Table 1. • Day 1, mean PRI was similar in both groups (83.9% vs. 83.2%), but PRI on Day 7 was significantly higher in the Omp group (51.4% vs.. 39.8%), (p< 0.0001) Figure 1. • Clopidogrel “poor” responders (defined as PRI >50%) were more common in the Omp group 60.9% vs. 26.7% in the placebo group (p < 0.0001). • The odds ratio of being a clopidogrel “poor” responder when treated with Omp was 4.31 (95% CI 2.0 to 9.2).

  18. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Conclusions: • Omp significantly decreased the effect of clopidogrel on platelet activation as tested by VASP phosphorylation. • Clinical implications of this study suggest that 1/3 of patients on clopidogrel alone are unprotected against ACS (PRI > 50%) and that patients co-treated with Omp have double the risk of ACS (60.9% have PRI > 50%). • The empiric prescription of Omp to prevent the potential of gastrointestinal bleeding caused by aspirin-clopidogrel antiplatelet therapy should be stopped. Risk stratification for GI complications should guide Omp use in these patients.

  19. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Reviewer Comments Gilard, et al, do not answer the following questions? • Although all of the PPIs are prodrugs with some metabolism through the CYP450. Each PPI has unique CYP450 metabolic pathways. This study does not determine if all PPIs convey the same negative effect on clopidogrel (PRI > 50%) as shown with Omp. PPIPrimary Pathway(Secondary pathway) • Omperazole CYP2C19 (CYP3A4) • Esomperazole CYP3A4 (CYP2C19) • Lansoprazole CYP3A4 (CYP2C19,CYP1A) • Dexlansoprazole CYP2C19 (CYP3A4) • Rabeprazole CYP2C19 + CYP3A4 • Pantoprazole CYP2C9 (CYP2C19sulfate conjugation) • The investigators did not evaluate for CYP2C19 polymorphisms or other confounding variables that may have influenced clopidogrel hepatic metabolism and explained high PRI (>50%) seen in 30% of the placebo group.

  20. Gilard M, et al. J Am Coll Cardiol 2008;51:256-60. Reviewer Comments • Dr. Gilard and colleagues are commended for using a readily available clinical assay (VASP phosphorylation) to demonstrate the effects of Omp on clopidogrel inhibition of the ACS marker, PRI. • The study is well designed, the results striking and with important negative clinical implication for the coadministration of omp and clopidogrel among patients at risk for ACS. • This study design should be applied in a similar fashion to evaluate the effect of other PPIs on clopidogrel and the ACS risk measured by PRI > 50%. • For now, we should all use restraint in the prescription of PPI among patients on clopidogrel and follow the current recommendation of the FDA until further studies are available. http://www.fda.gov/Cder/drug/early_comm/clopidogrel_bisulfate.htm

  21. http://www.fda.gov/Cder/drug/early_comm/clopidogrel_bisulfate.htmhttp://www.fda.gov/Cder/drug/early_comm/clopidogrel_bisulfate.htm The identification of increased risk for Acute Coronary Syndrome when at risk cardiac patients receiving clopidogrel are concomitantly given PPIs has lead to the Food & Drug Administration to issue the following warning: • “Healthcare providers should continue to prescribe and patients should continue to take clopidogrel as directed, because clopidogrel has demonstrated benefits in preventing blood clots that could lead to a heart attack or stroke.” • “Healthcare providers should re-evaluate the need for starting or continuing treatment with a PPI, including Prilosec OTC, in patients taking clopidogrel.” • “Patients taking clopidogrel should consult with their healthcare provider if they are currently taking or considering taking PPI, including Prilosec OTC.”

More Related